The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR). This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs). In Australia, dealings with GMOs in clinical research requires authorisation under the Gene Technology
The post Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand appeared first on Pharma Mirror Magazine.
